Related Experiment Video

Updated: May 2, 2026

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models
03:42

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models

Published on: September 27, 2024

1.9K

The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer

Tamina Rawnaq1, Luisa Dietrich, Gerrit Wolters-Eisfeld

  • 1Authors' Affiliations: Department of General, Visceral and Thoracic Surgery, Experimental Oncology and 2Institute for Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Molecular Cancer Research : MCR
|February 26, 2014
PubMed
Abstract

Insights

Midkine (MK) is elevated in pancreatic ductal adenocarcinoma (PDAC), promoting cancer growth and survival. Targeting MK offers a promising new therapeutic strategy for this deadly disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis.
  • Current targeted therapies for PDAC are limited.
  • Midkine (MK) is implicated in various cancers, promoting angiogenesis, proliferation, migration, and survival.

Purpose of the Study:

  • To investigate the molecular role of midkine (MK) in pancreatic cancer.
  • To evaluate MK as a potential therapeutic target and biomarker in PDAC.

Main Methods:

  • Analysis of MK expression in PDAC and other pancreatic cancer subtypes.
  • ELISA for MK detection in clinical serum specimens.
  • MK knockdown studies in vitro.
  • Analysis of upstream signaling pathways (TNF-α, EGF).

Main Results:

  • MK is elevated in PDAC and differentially expressed across pancreatic cancer subtypes.
  • Normal pancreatic cells do not express MK.
  • MK knockdown reduced proliferation and migration in vitro.
  • TNF-α and EGF were identified as key inducers of MK expression in PDAC.

Conclusions:

  • Midkine (MK) plays a significant role in promoting pancreatic ductal adenocarcinoma (PDAC) progression.
  • Novel upstream signaling pathways (TNF-α, EGF) inducing MK expression were identified.
  • MK represents an attractive and actionable therapeutic target for PDAC.

More Related Videos

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

13.3K
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

1.1K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.5K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K